For quotations, please use our online quotation form, and you may also contact us by
sales@neoscientific.com
+1-888.733.6849
+1-617.299.7367 (Int’l)
+1-888.733.6849
+1-617.299.7367 (Int’l)
Reactivity | Human Mouse Rat |
Tested applications | WB IHC |
Recommended Dilution | WB 1:500 - 1:2000 IHC 1:50 - 1:100 |
Calculated MW | 100kDa |
Observed MW | Refer to figures |
Immunogen | A synthetic peptide of human CBL |
Storage Buffer | Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
Synonym | CBL2; NSLL; C-CBL; RNF55; FRA11B; |
Western blot analysis of extracts of various cells, using CBL antibody.
Immunohistochemistry of paraffin-embedded human prostate using CBL antibody at dilution of 1:200 (40x lens).
Immunohistochemistry of paraffin-embedded mouse lung using CBL antibody at dilution of 1:200 (40x lens).
Immunohistochemistry of paraffin-embedded mouse stomach using CBL antibody.
Immunohistochemistry of paraffin-embedded rat kidney using CBL antibody.
Immunohistochemistry of paraffin-embedded mouse liver using CBL antibody.
This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.
N/A